We performed a retrospective study including patients with stage IV NSCLC who were treated with anti-PD-1 drugs in first or advanced lines of therapy in the Affiliated Tumor Hospital of Nantong University. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.